Vats Kusum, Subramanian Suresh, Mathur Anupam, Sarma Haladhar Dev, Banerjee Sharmila
Radiopharmaceuticals Chemistry Section, Radiochemistry & Isotope Group, Bhabha Atomic Research Centre, Mumbai 400085, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai 400094, India.
Isotope Production and Applications Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
Bioorg Med Chem Lett. 2017 Mar 1;27(5):1329-1332. doi: 10.1016/j.bmcl.2016.03.090. Epub 2016 Mar 30.
Folate receptors (FR) are over-expressed on a wide variety of tumor cells and are a potential molecular target for radiolabeled folates. In this respect, several SPECT and PET based radiofolates have been evaluated in the past albeit with their high renal uptake posing limitation towards their clinical use. To overcome this, a new Tc labeled folic acid was synthesized via the use of [TcN(PNP)] metal fragment, where the presence of the latter pharmacophore redirects in vivo clearance via the hepatobiliary pathway. In this respect, folic acid was derivatized at the γ-acid group with a cysteine BFCA (bifunctional chelating agent) and subsequently reacted with the preformed [TcN] intermediate in presence of PNP2 (bisphosphine) ligand, to yield the final complex. While preliminary, in vivo distribution of the complex exhibited high association of activity with liver and intestines and provided support to the rationality of the present design as clearance of labeled folic acid could be effected via the hepatic route, the in vitro studies of the folic acid-cysteine conjugate carried out in KB-31 cells, did not show much promise with reduction in receptor affinity in comparison with the native folic acid. The route followed herein to prepare a folic-acid based radiotracer constitutes the first report of radiolabeling folic acid using the [TcN(PNP)] as a radiosynthon. Modification in the structure of conjugate by linking the BFCA through a long-chain linker can be envisaged to improve the affinity of [TcN(PNP)]-folic acid complex towards FRs.
叶酸受体(FR)在多种肿瘤细胞上过度表达,是放射性标记叶酸的潜在分子靶点。在这方面,过去已经评估了几种基于单光子发射计算机断层扫描(SPECT)和正电子发射断层扫描(PET)的放射性叶酸,尽管它们的高肾脏摄取限制了其临床应用。为了克服这一问题,通过使用[TcN(PNP)]金属片段合成了一种新的锝标记叶酸,其中后一种药效基团的存在通过肝胆途径改变了体内清除方式。在这方面,叶酸在γ-酸基团处用半胱氨酸双功能螯合剂(BFCA)进行衍生化,随后在双膦(PNP2)配体存在下与预先形成的[TcN]中间体反应,生成最终的配合物。虽然是初步研究,但该配合物的体内分布显示出活性与肝脏和肠道的高度关联,并支持了当前设计的合理性,因为标记叶酸的清除可以通过肝脏途径实现。在KB-31细胞中进行的叶酸-半胱氨酸缀合物的体外研究与天然叶酸相比,受体亲和力降低,没有显示出太大的前景。本文制备基于叶酸的放射性示踪剂所采用的方法是首次报道使用[TcN(PNP)]作为放射性合成子对叶酸进行放射性标记。可以设想通过长链连接子连接BFCA来修饰缀合物的结构,以提高[TcN(PNP)]-叶酸配合物对叶酸受体(FRs)的亲和力。